Findings of a phase 2b study indicated that use of tildrakizumab was associated with significant improvements in joint and skin manifestations of patients with psoriatic arthritis (PsA), although ...
Risankizumab is an effective treatment option for patients with psoriatic arthritis (PsA), according to a recent meta-analysis. Risankizumab showed superior efficacy across multiple outcomes compared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results